.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 9,309,279

« Back to Dashboard

Details for Patent: 9,309,279

Title:Macrocyclic hepatitis C serine protease inhibitors
Abstract: The present invention relates to novel macrocyclic compounds and methods of treating a hepatitis C infection in a subject in need of such therapy with said macrocyclic compounds. The present invention further relates to pharmaceutical compositions comprising the compounds of the present invention, or pharmaceutically acceptable salts, esters, or prodrugs thereof, in combination with a pharmaceutically acceptable carrier or excipient.
Inventor(s): Ku; Yiyin (Buffalo Grove, IL), McDaniel; Keith F. (Wauconda, IL), Chen; Hui-Ju (Grayslake, IL), Shanley; Jason P. (Chicago, IL), Kempf; Dale J. (Libertyville, IL), Grampovnik; David J. (Waukegan, IL), Sun; Ying (Waltham, MA), Liu; Dong (Newton, MA), Gai; Yonghua (North Grafton, MA), Or; Yat Sun (Watertown, MA), Wagaw; Seble H. (Evanston, IL), Engstrom; Kenneth (Mundelein, IL), Grieme; Tim (Chicago, IL), Sheikh; Ahmad (Deerfield, IL), Mei; Jianzhang (Lake Forest, IL)
Assignee: AbbVie Inc. (Abbott Park, IL) Enanta Pharmaceuticals, Inc. (Boston, MA)
Filing Date:Jan 31, 2014
Application Number:14/170,199
Claims:1. A method of preparing a compound of formula I, or a pharmaceutically acceptable salt thereof: ##STR00030## the method comprising deprotecting ##STR00031## to form ##STR00032## which is then reacted with H-G to form said compound, wherein PG.sub.N is an amino protecting group and PG.sub.C is a carboxylic acid protecting group; J is absent, optionally substituted alkylene, optionally substituted alkenylene, optionally substituted alkynylene, --C(O)--, --O--C(O)--,--N(R.sub.3)--C(O)--, --C(S)--, --C(.dbd.NR.sub.4)--, --S(O)--, --S(O.sub.2)--, or --N(R.sub.3)--; A is optionally substituted alkyl, optionally substituted alkenyl, or optionally substituted alkynyl, each containing 0, 1, 2, or 3 heteroatoms selected from O, S, or N; optionally substituted aryl, optionally substituted arylalkyl, optionally substituted alkoxy, optionally substituted heteroaryl, optionally substituted heterocyclic, or optionally substituted carbocyclic; Each R.sub.1 is independently selected from (i) halogen, hydroxy, amino, --CN, --CF.sub.3, --N.sub.3, --NO.sub.2, --OR.sub.4, --SR.sub.4, --SOR.sub.4, --SO.sub.2R.sub.4, --N(R.sub.3)S(O).sub.2--R.sub.4, --N(R.sub.3) S(O.sub.2)NR.sub.3R.sub.4, --NR.sub.3R.sub.4, --C(O)OR.sub.4, --C(O)R.sub.4, --C(O)NR.sub.3R.sub.4, or --N(R.sub.3)C(O)R.sub.4; (ii) optionally substituted aryl; (iii) optionally substituted heteroaryl; (iv) optionally substituted heterocyclic; (v) optionally substituted carbocyclic; or (vi) optionally substituted alkyl, optionally substituted alkenyl, or optionally substituted alkynyl, each containing 0, 1, 2, or 3 heteroatoms selected from O, S, or N; G is -E-R.sub.5; wherein E is absent; optionally substituted alkylene, optionally substituted alkenylene, optionally substituted alkynylene, each containing 0, 1, 2, or 3 heteroatoms selected from O, S, or N; or --O--, --S--, --N(R.sub.3)--, --N(R.sub.3)S(O.sub.p)--, --N(R.sub.3)C(O)--, --N(R.sub.3) C(O)S(O.sub.p)--, --OS(O.sub.p)--, --C(O)S(O.sub.p)--, or --C(O)N(R.sub.3)S(O.sub.p)--; p is 0, 1, or 2; R.sub.5 is H; optionally substituted alkyl, optionally substituted alkenyl, or optionally substituted alkynyl, each containing 0, 1, 2, or 3 heteroatoms selected from O, S, or N; optionally substituted carbocyclic, optionally substituted heterocyclic, optionally substituted aryl, or optionally substituted heteroaryl; R.sub.3 and R.sub.4 are each independently selected at each occurrence from the following: optionally substituted alkyl, optionally substituted alkenyl or optionally substituted alkynyl, each containing 0, 1, 2, or 3 heteroatoms selected from O, S, or N; optionally substituted aryl; optionally substituted heteroaryl; optionally substituted heterocyclic; optionally substituted carbocyclic; or hydrogen; L is absent or is selected from optionally substituted alkylene, optionally substituted alkenylene or optionally substituted alkynylene, each containing 0, 1, 2, or 3 heteroatoms selected from O, S, or N; Y is N or --C(R'')--; wherein A, R.sub.1, R' and/or R'' can be taken together form a ring; j=0, 1, 2, 3, or 4; k=0, 1, 2, or 3; m=0, 1, or 2; n is 0, 1, 2, 3, or 4; denotes a carbon-carbon single or double bond, wherein if Y is N, then R' is optionally substituted heterocyclic or optionally substituted carbocyclic, and comprises two or more fused rings, and wherein R' is not ##STR00033## wherein if Y is --C(R'')--, then R' and R'' taken together with the carbon atoms to which they are attached form an aryl or heteroaryl ring, each said ring is optionally substituted; provided that said compound is not tert-butyl (2R,6S,13aS,14aR,16aS,Z)-2-(3-(benzo[d]thiazol-2-yl)quinoxalin-2-yloxy)-1- 4a-(cyclopropylsulfonylcarbamoyl)-5,16-dioxo-1,2,3,5,6,7,8,9,10,11,13a,14,- 14a,15,16,16a-hexadecahydrocyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopenta- decin-6-ylcarbamate.

2. The method of claim 1, wherein R' is H, Y is N, and wherein k=3, j=1, and L is absent.

3. The method of claim 2, wherein R.sub.1 is hydrogen or halogen, E is --NHS(O)-- or --NHS(O.sub.2)--, and R.sub.5 is cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, pyridinyl, pyrimidinyl, furanyl, thienyl, pyrrolyl, pyrazolyl, pyrrolidinyl, morpholinyl, piperidinyl, piperazinyl, or imidazolyl, each of which is optionally substituted.

4. The method of claim 2, wherein J is --C(O)-- and A is optionally substituted --C.sub.1-C.sub.8 alkyl, containing 0, 1, 2, or 3 heteroatoms selected from O, S, or N; optionally substituted aryl, optionally substituted --C.sub.1-C.sub.8 alkoxy, optionally substituted heteroaryl, optionally substituted --C.sub.3-C.sub.12 cycloalkyl, or optionally substituted --C.sub.3-C.sub.12 heterocycloalkyl.

5. The method of claim 1, wherein Y is --C(R'')--, and R' and R'' taken together with the carbon atoms to which they are attached form an aryl or heteroaryl ring, each said ring is optionally substituted, and wherein k=3, j=1 and L is absent.

6. The method of claim 5, wherein R.sub.1 is hydrogen or halogen; E is --NHS(O)-- or --NHS(O.sub.2)--, and R.sub.5 is cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, pyridinyl, pyrimidinyl, furanyl, thienyl, pyrrolyl, pyrazolyl, pyrrolidinyl, morpholinyl, piperidinyl, piperazinyl, or imidazolyl, each of which is optionally substituted.

7. The method of claim 5, wherein J is --C(O)-- and A is optionally substituted --C.sub.1-C.sub.8 alkyl, containing 0, 1, 2, or 3 heteroatoms selected from O, S, or N; optionally substituted aryl, optionally substituted --C.sub.1-C.sub.8 alkoxy, optionally substituted heteroaryl, optionally substituted --C.sub.3-C.sub.12 cycloalkyl, or optionally substituted --C.sub.3-C.sub.12 heterocycloalkyl.

8. The method of claim 5, wherein R' and R'' together form an optionally substituted aryl.

9. The method of claim 5, wherein R' and R'', and the atoms to which each is attached, form an aryl which is substituted by (R.sub.2).sub.x, wherein each R.sub.2 is independently selected from (i) halogen, hydroxy, amino, --CN, --CF.sub.3, --N.sub.3, --NO.sub.2, --OR.sub.4, --SR.sub.4, --SOR.sub.4, --SO.sub.2R.sub.4, --NHS(O.sub.2)--R.sub.4, --NHS(O.sub.2)NR.sub.3R.sub.4, --NR.sub.3R.sub.4, --C(O)OR.sub.4, --C(O)R.sub.4, --C(O)NR.sub.3R.sub.4, or --N(R.sub.3)C(O)R4; (ii) optionally substituted aryl; (iii) optionally substituted heteroaryl; (iv) optionally substituted heterocyclic; (v) optionally substituted carbocyclic; or (iv) optionally substituted alkyl, optionally substituted alkenyl, or optionally substituted alkynyl, each containing 0, 1, 2, or 3 heteroatoms selected from O, S, or N; and x is 0, 1, 2, 3, or 4.

10. The method of claim 1, wherein the compound of formula I is selected from the following: (2) (2R,6S,13aS,14aR,16aS,Z)-2-(3-(benzo[d]thiazol-2-yl)quinoxalin-2-yloxy)-N- -(cyclopropylsulfonyl)-6-(isonicotinamido)-5,16-dioxo-1,2,3,5,6,7,8,9,10,1- 1,13a,14,14a,15,16,16a-hexadecahydrocyclopropa[e]pyrrolo[1,2-a][1,4]diazac- yclopentadecine-14a-carboxamide; (3) (2R,6S,13aS,14aR,16aS,Z)-2-(3-(benzo[d]thiazol-2-yl)quinoxalin-2-yloxy)-N- -(cyclopropylsulfonyl)-6-(2-fluorobenzamido)-5,16-dioxo-1,2,3,5,6,7,8,9,10- ,11,13a,14,14a,15,16,16a-hexadecahydrocyclopropa[e]pyrrolo[1,2-a][1,4]diaz- acyclopentadecine-14a-carboxamide; (4) N-((2R,6S,13aS,14aR,16aS,Z)-2-(3-(benzo[d]thiazol-2-yl)quinoxalin-2-yloxy- )-14a-(cyclopropylsulfonylcarbamoyl)-5,16-dioxo-1,2,3,5,6,7,8,9,10,11,13a,- 14,14a,15,16,16a-hexadecahydrocyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclope- ntadecin-6-yl)-5-methylisoxazole-3-carboxamide; (5) (2R,6S,13aS,14aR,16aS,Z)-2-(3-(benzo[d]thiazol-2-yl)quinoxalin-2-yloxy)-N- -(cyclopropylsulfonyl)-6-(5-methylpyrazine-2-carboxamido)-5,16-dioxo-1,2,3- ,5,6,7,8,9,10,11,13a,14,14a,15,16,16a-hexadecahydrocyclopropa[e]pyrrolo[1,- 2-a][1,4]diazacyclopentadecine-14a-carboxamide; (6) N-((2R,6S,13aS,14aR,16aS,Z)-2-(3-(benzo[d]thiazol-2-yl)quinoxalin-2-yloxy- )-14a-(cyclopropylsulfonylcarbamoyl)-5,16-dioxo-1,2,3,5,6,7,8,9,10,11,13a,- 14,14a,15,16,16a-hexadecahydrocyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclope- ntadecin-6-yl)isoxazole-5-carboxamide; (7) N-((2R,6S,13aS,14aR,16aS,Z)-2-(3-(benzo[d]thiazol-2-yl)quinoxalin-2-yloxy- )-14a-(cyclopropylsulfonylcarbamoyl)-5,16-dioxo-1,2,3,5,6,7,8,9,10,11,13a,- 14,14a,15,16,16a-hexadecahydrocyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclope- ntadecin-6-yl)thiazole-4-carboxamide; (8) (2R,6S,13aS,14aR,16aS,Z)-2-(3-(benzo[d]thiazol-2-yl)quinoxalin-2-yloxy)-N- -(cyclopropylsulfonyl)-6-(1-methyl-1H-pyrazole-3-carboxamido)-5,16-dioxo-1- ,2,3,5,6,7,8,9,10,11,13a,14,14a,15,16,16a-hexadecahydrocyclopropa[e]pyrrol- o[1,2-a][1,4]diazacyclopentadecine-14a-carboxamide; (9) (2R,6S,13aS,14aR,16aS,Z)-2-(3-(benzo[d]thiazol-2-yl)quinoxalin-2-yloxy)-N- -(cyclopropylsulfonyl)-5,16-dioxo-6-(pyrimidine-4-carboxamido)-1,2,3,5,6,7- ,8,9,10,11,13a,14,14a,15,16,16a-hexadecahydrocyclopropa[e]pyrrolo[1,2-a][1- ,4]diazacyclopentadecine-14a-carboxamide; (10) (2R,6S,13aS,14aR,16aS,Z)-2-(3-(benzo[d]thiazol-2-yl)quinoxalin-2-yloxy)-N- -(cyclopropylsulfonyl)-6-(1,3-dimethyl-1H-pyrazole-4-carboxamido)-5,16-dio- xo-1,2,3,5,6,7,8,9,10,11,13a,14,14a,15,16,16a-hexadecahydrocyclopropa[e]py- rrolo[1,2-a][1,4]diazacyclopentadecine-14a-carboxamide; (11) (2R,6S,13aS,14aR,16aS,Z)-2-(3-(benzo[d]thiazol-2-yl)quinoxalin-2-yloxy)-N- -(cyclopropylsulfonyl)-6-(3-fluorobenzamido)-5,16-dioxo-1,2,3,5,6,7,8,9,10- ,11,13a,14,14a,15,16,16a-hexadecahydrocyclopropa[e]pyrrolo[1,2-a][1,4]diaz- acyclopentadecine-14a-carboxamide; (12) tert-butyl (2R,6S,13aS,14aR,16aS,Z)-2-(3-(benzofuran-2-yl)quinoxalin-2-yloxy)-14a-(c- yclopropylsulfonylcarbamoyl)-5,16-dioxo-1,2,3,5,6,7,8,9,10,11,13a,14,14a,1- 5,16,16a-hexadecahydrocyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecin- -6-ylcarbamate; (13) N-((2R,6S,13aS,14aR,16aS,Z)-2-(3-(benzofuran-2-yl)quinoxalin-2-yloxy)-14a- -(cyclopropylsulfonylcarbamoyl)-5,16-dioxo-1,2,3,5,6,7,8,9,10,11,13a,14,14- a,15,16,16a-hexadecahydrocyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentade- cin-6-yl)-5-methylisoxazole-3-carboxamide; (14) (2R,6S,13aS,14aR,16aS,Z)-2-(3-(benzofuran-2-yl)quinoxalin-2-yloxy)-N-(cyc- lopropylsulfonyl)-6-(5-methylpyrazine-2-carboxamido)-5,16-dioxo-1,2,3,5,6,- 7,8,9,10,11,13a,14,14a,15,16,16a-hexadecahydrocyclopropa[e]pyrrolo[1,2-a][- 1,4]diazacyclopentadecine-14a-carboxamide; (15) (2R,6S,13aS,14aR,16aS,Z)-2-(3-(benzofuran-2-yl)quinoxalin-2-yloxy)-N-(cyc- lopropylsulfonyl)-6-(1-methyl-1H-pyrazole-3-carboxamido)-5,16-dioxo-1,2,3,- 5,6,7,8,9,10,11,13a,14,14a,15,16,16a-hexadecahydrocyclopropa[e]pyrrolo[1,2- -a][1,4]diazacyclopentadecine-14a-carboxamide; (16) (2R,6S,13aS,14aR,16aS,Z)-2-(3-(benzofuran-2-yl)quinoxalin-2-yloxy)-N-(cyc- lopropylsulfonyl)-6-(1,5-dimethyl-1H-pyrazole-3-carboxamido)-5,16-dioxo-1,- 2,3,5,6,7,8,9,10,11,13a,14,14a,15,16,16a-hexadecahydrocyclopropa[e]pyrrolo- [1,2-a][1,4]diazacyclopentadecine-14a-carboxamide; and (17) (2R,6S,13aS,14aR,16aS,Z)-2-(3-(benzofuran-2-yl)quinoxalin-2-yloxy)-N-(cyc- lopropylsulfonyl)-5,16-dioxo-6-(pyrimidine-4-carboxamido)-1,2,3,5,6,7,8,9,- 10,11,13a,14,14a,15,16,16a-hexadecahydrocyclopropa[e]pyrrolo[1,2-a][1,4]di- azacyclopentadecine-14a-carboxamide.

11. The method of claim 1, wherein the compound of formula I is selected from the following: (24) tert-butyl (2R,6S,13aS,14aR,16aS,Z)-14a-(cyclopropylsulfonylcarbamoyl)-5,16-dioxo-2-- (phenanthridin-6-yloxy)-1,2,3,5,6,7,8,9,10,11,13a,14,14a,15,16,16a-hexadec- ahydrocyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecin-6-ylcarbamate; (25) (2R,6S,13aS,14aR,16aS,Z)--N-(cyclopropylsulfonyl)-5,16-dioxo-2-(phen- anthridin-6-yloxy)-6-(pyrazine-2-carboxamido)-1,2,3,5,6,7,8,9,10,11,13a,14- ,14a,15,16,16a-hexadecahydrocyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopent- adecine-14a-carboxamide; (26) Cyclopentyl (2R,6S,13aS,14aR,16aS,Z)-14a-(cyclopropylsulfonylcarbamoyl)-5,16-dioxo-2-- (phenanthridin-6-yloxy)-1,2,3,5,6,7,8,9,10,11,13a,14,14a,15,16,16a-hexadec- ahydrocyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecin-6-ylcarbamate; (27) (2R,6S,13aS,14aR,16aS,Z)--N-(cyclopropylsulfonyl)-6-(5-methyl-1H-pyr- azole-3-carboxamido)-5,16-dioxo-2-(phenanthridin-6-yloxy)-1,2,3,5,6,7,8,9,- 10,11,13a,14,14a,15,16,16a-hexadecahydrocyclopropa[e]pyrrolo[1,2-a][1,4]di- azacyclopentadecine-14a-carboxamide; (28) N-((2R,6S,13aS,14aR,16aS,Z)-14a-(cyclopropylsulfonylcarbamoyl)-5,16-dioxo- -2-(phenanthridin-6-yloxy)-1,2,3,5,6,7,8,9,10,11,13a,14,14a,15,16,16a-hexa- decahydrocyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecin-6-yl)-5-meth- ylisoxazole-3-carboxamide; (29) (2R,6S,13aS,14aR,16aS,Z)--N-(cyclopropylsulfonyl)-6-(5-methylpyrazine-2-c- arboxamido)-5,16-dioxo-2-(phenanthridin-6-yloxy)-1,2,3,5,6,7,8,9,10,11,13a- ,14,14a,15,16,16a-hexadecahydrocyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclop- entadecine-14a-carboxamide; (30) N-((2R,6S,13aS,14aR,16aS,Z)-14a-(cyclopropylsulfonylcarbamoyl)-5,16-dioxo- -2-(phenanthridin-6-yloxy)-1,2,3,5,6,7,8,9,10,11,13a,14,14a,15,16,16a-hexa- decahydrocyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecin-6-yl)thiazol- e-5-carboxamide; (31) (2R,6S,13aS,14aR,16aS,Z)--N-(cyclopropylsulfonyl)-6-(2-fluorobenzamido)-5- ,16-dioxo-2-(phenanthridin-6-yloxy)-1,2,3,5,6,7,8,9,10,11,13a,14,14a,15,16- ,16a-hexadecahydrocyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14- a-carboxamide; (32) (2R,6S,13aS,14aR,16aS,Z)--N-(cyclopropylsulfonyl)-5,16-dioxo-2-(phenanthr- idin-6-yloxy)-6-(pyridazine-4-carboxamido)-1,2,3,5,6,7,8,9,10,11,13a,14,14- a,15,16,16a-hexadecahydrocyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentade- cine-14a-carboxamide; (33) (2R,6S,13aS,14aR,16aS,Z)--N-(cyclopropylsulfonyl)-5,16-dioxo-2-(phenanthr- idin-6-yloxy)-6-(pyrimidine-4-carboxamido)-1,2,3,5,6,7,8,9,10,11,13a,14,14- a,15,16,16a-hexadecahydrocyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentade- cine-14a-carboxamide; (34) (2R,6S,13aS,14aR,16aS,Z)--N-(cyclopropylsulfonyl)-6-(1-methyl-1H-pyrazole- -3-carboxamido)-5,16-dioxo-2-(phenanthridin-6-yloxy)-1,2,3,5,6,7,8,9,10,11- ,13a,14,14a,15,16,16a-hexadecahydrocyclopropa[e]pyrrolo[1,2-a][1,4]diazacy- clopentadecine-14a-carboxamide; (35) (2R,6S,13aS,14aR,16aS,Z)--N-(cyclopropylsulfonyl)-6-(2-hydroxy-2-methylpr- opanamido)-5,16-dioxo-2-(phenanthridin-6-yloxy)-1,2,3,5,6,7,8,9,10,11,13a,- 14,14a,15,16,16a-hexadecahydrocyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclope- ntadecine-14a-carboxamide; (36) (2R,6S,13aS,14aR,16aS,Z)--N-(cyclopropylsulfonyl)-6-(1,5-dimethyl-1H-pyra- zole-3-carboxamido)-5,16-dioxo-2-(phenanthridin-6-yloxy)-1,2,3,5,6,7,8,9,1- 0,11,13a,14,14a,15,16,16a-hexadecahydrocyclopropa[e]pyrrolo[1,2-a][1,4]dia- zacyclopentadecine-14a-carboxamide; (37) Cyclopentyl (2R,6S,13aS,14aR,16aS,Z)-14a-(cyclopropylsulfonylcarbamoyl)-2-(2-fluoroph- enanthridin-6-yloxy)-5,16-dioxo-1,2,3,5,6,7,8,9,10,11,13a,14,14a,15,16,16a- -hexadecahydrocyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecin-6-ylcar- bamate; (38) tert-Butyl (2R,6S,13aS,14aR,16aS,Z)-14a-(cyclopropylsulfonylcarbamoyl)-2-(2,9-difluo- rophenanthridin-6-yloxy)-5,16-dioxo-1,2,3,5,6,7,8,9,10,11,13a,14,14a, 15,16,16a-hexadecahydrocyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadec- in-6-ylcarbamate; (39) tert-butyl (2R,6S,13aR,14aR,16aS)-14a-(cyclopropylsulfonylcarbamoyl)-5,16-dioxo-2-(p- henanthridin-6-yloxy)octadecahydrocyclopropa[e]pyrrolo[1,2-a][1,4]diazacyc- lopentadecin-6-ylcarbamate; (40) Cyclopentyl (2R,6S,13aR,14aR,16aS)-14a-(cyclopropylsulfonylcarbamoyl)-5,16-dioxo-2-(p- henanthridin-6-yloxy)octadecahydrocyclopropa[e]pyrrolo[1,2-a][1,4]diazacyc- lopentadecin-6-ylcarbamate; and (41) tert-Butyl (2R,6S,13aR,14aR,16aS)-5,16-dioxo-2-(phenanthridin-6-yloxy)-14a-(thiophen- -2-ylsulfonylcarbamoyl)octadecahydrocyclopropa[e]pyrrolo[1,2-a][1,4]diazac- yclopentadecin-6-ylcarbamate.

12. The method of claim 1, wherein E is --N(R.sub.3)S(O.sub.p)--, R.sub.3 is H, p is 2, and R.sub.5 is optionally substituted carbocyclic.

13. The method of claim 12, wherein R.sub.5 is optionally substituted cyclopropyl.

14. The method of claim 1, wherein E is --N(R.sub.3)S(O.sub.p)--, R.sub.3 is H, p is 2, and R.sub.5 is optionally substituted heteroaryl.

15. The method of claim 1, wherein J is --C(O)-- and A is optionally substituted heteroaryl.

16. The method of claim 15, wherein A is substituted heteroaryl.

17. The method of claim 15, wherein A is pyrazinyl.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc